Sampo plc
Sampo Group's results for January–September 2024 will be published on 6 November 2024
Sampo Group's results for January–September 2024 will be published on 6 November 2024
Sampo plc, press release, 30 October 2024 at 10:00 am EET
Sampo Group's results for January–September 2024 will be published on 6 November 2024
Sampo Group will publish the Interim Statement for January–September 2024 on 6 November between 9:30 am and 10:00 am Finnish time (7:30-8:00 am UK time). The report, the investor presentation, and a video review with Group CEO Torbjörn Magnusson will be available at www.sampo.com/result.
Conference call
6 November at 2:30 pm Finnish time (12:30 pm UK time)
To ask questions, please join the teleconference by registering using the following link: https://palvelu.flik.fi/teleconference/?id=50048816.
After the registration, you will be provided with phone numbers and a conference ID to access the conference. To ask a question, please press #5 on your telephone keypad to enter the queue.
Group CEO Torbjörn Magnusson, Group CFO Knut Arne Alsaker, CEO of If P&C Morten Thorsrud, CEO of Hastings Toby van der Meer, and Head of IR Sami Taipalus will attend the conference call for investors and analysts.
The conference call can also be followed live at www.sampo.com/result. A recorded version and a transcript will later be available at the same address.
SAMPO PLC
Investor Relations and Group Communications
Further information:
Maria Silander
Communications Manager, Media Relations
tel. +358 10 516 0031
Distribution:
The principal media
www.sampo.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
dsm-firmenich2.6.2025 13:12:47 CEST | Press release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Novonesis (Novozymes A/S)2.6.2025 13:05:24 CEST | Press release
Novonesis completes acquisition of dsm-firmenichs’s share of the Feed Enzyme Alliance
Outlook Therapeutics, Inc.2.6.2025 13:00:00 CEST | Press release
Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD
Denodo Technologies Inc. (“Denodo”)2.6.2025 13:00:00 CEST | Press release
Denodo University Challenge Now Open: Data and AI for Real-World Impact
Nykredit Realkredit A/S2.6.2025 12:44:05 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom